세계의 수면무호흡증 진단 및 치료 기기 시장 예측 : 제품 유형별, 기술별, 유통 채널별, 용도별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Sleep Apnea Diagnostic and Therapeutic Devices Market is accounted for $7.0 billion in 2025 and is expected to reach $13.3 billion by 2032 growing at a CAGR of 9.6% during the forecast period. Sleep apnea diagnostic and therapeutic devices are medical technologies designed to detect, monitor, and treat sleep apnea-a disorder characterized by repeated interruptions in breathing during sleep. Diagnostic devices, such as polysomnography systems, home sleep testing kits, and oximeters, record physiological parameters like airflow, oxygen levels, and respiratory effort to identify apnea episodes. Therapeutic devices, including continuous positive airway pressure (CPAP) machines, bi-level positive airway pressure (BiPAP) devices, oral appliances, and adaptive servo-ventilators, help maintain open airways and ensure proper breathing throughout sleep. These devices play a crucial role in improving sleep quality, preventing complications, and enhancing overall health.

Market Dynamics:

Driver:

Rising prevalence of sleep apnea

Sleep-disordered breathing affects millions globally and contributes to cardiovascular neurological and metabolic complications. Platforms support early detection symptom monitoring and treatment adherence using CPAP BiPAP and wearable diagnostics. Integration with telehealth AI-based screening and remote monitoring enhances accessibility and clinical outcomes. Demand for scalable and non-invasive solutions is rising across aging populations and high-risk cohorts. These dynamics are propelling platform deployment across sleep medicine and chronic disease management ecosystems.

Restraint:

High cost of therapy and ongoing consumable costs

Devices require upfront investment and recurring expenses for masks tubing and filters that strain patient budgets. Reimbursement gaps and fragmented payer policies further complicate access and affordability. Enterprises face challenges in aligning pricing models with clinical outcomes and patient engagement. Vendors must offer subscription models bundled care and cost-transparent platforms to improve uptake. These constraints continue to hinder platform maturity across low-income and underinsured populations.

Opportunity:

Shift to home-based testing and telehealth

Patients increasingly prefer at-home sleep studies and virtual consultations to avoid clinical wait times and improve convenience. Platforms integrate with mobile apps cloud-based analytics and wearable sensors to deliver real-time insights and personalized therapy. Demand for scalable and privacy-compliant solutions is rising across primary care employer wellness and insurance-backed programs. Vendors offer modular kits AI-driven triage and outcome dashboards to support hybrid care models. These trends are fostering growth across home-centric and digitally enabled sleep apnea ecosystems.

Threat:

Limited awareness & infrastructure in developing markets

Many regions lack trained sleep specialists diagnostic labs and reimbursement frameworks to support widespread screening and treatment. Cultural stigma low health literacy and limited digital access further degrade demand and engagement. Enterprises face challenges in deploying scalable and regionally adapted solutions across rural and peri-urban populations. Vendors must invest in education campaigns mobile-first platforms and public-private partnerships to expand reach. These limitations continue to restrict platform performance across underserved and infrastructure-limited geographies.

Covid-19 Impact:

The pandemic disrupted sleep clinics diagnostic workflows and therapy adherence across global markets. Lockdowns delayed in-lab studies and reduced access to respiratory therapists and sleep specialists. Post-pandemic recovery emphasized remote care digital diagnostics and patient self-management across sleep medicine. Investment in telemonitoring AI screening and home-based therapy surged across healthcare systems and consumer channels. Public awareness of sleep health and its link to immunity and mental well-being increased across policy and clinical circles. These shifts are reinforcing long-term investment in decentralized and digitally enabled sleep apnea infrastructure.

The therapeutic devices segment is expected to be the largest during the forecast period

The therapeutic devices segment is expected to account for the largest market share during the forecast period due to their clinical relevance scalability and widespread adoption across sleep apnea treatment. Platforms include CPAP BiPAP and auto-adjusting devices that support airway management and symptom relief. Integration with humidifiers data tracking and remote monitoring enhances adherence and personalization. Demand for compact quiet and travel-friendly devices is rising across homecare and outpatient settings. Vendors offer modular configurations cloud connectivity and patient engagement tools to support long-term therapy. These capabilities are boosting segment dominance across therapeutic sleep apnea platforms.

The complex sleep apnea syndrome segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the complex sleep apnea syndrome segment is predicted to witness the highest growth rate as diagnostic and therapeutic platforms expand across mixed and treatment-emergent apnea cases. Patients exhibit both obstructive and central apnea patterns requiring advanced monitoring and adaptive therapy. Platforms support multi-channel diagnostics algorithmic titration and integrated care across cardiology neurology and pulmonology. Integration with AI engines wearable sensors and cloud-based analytics enhances precision and responsiveness. Demand for scalable and clinically validated solutions is rising across specialty clinics and tertiary care centers. These dynamics are accelerating growth across complex sleep apnea syndrome platforms and services.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its healthcare infrastructure reimbursement frameworks and clinical adoption across sleep apnea technologies. Enterprises and providers deploy platforms across hospitals homecare and employer wellness programs to meet rising demand. Investment in AI diagnostics telehealth and therapeutic innovation supports scalability and personalization. Presence of leading vendors academic institutions and policy initiatives drives ecosystem maturity and adoption. Firms align sleep apnea strategies with chronic disease management value-based care and digital health goals.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as urbanization healthcare modernization and sleep disorder awareness converge across regional economies. Countries like China India Japan and South Korea scale platforms across public health employer wellness and consumer channels. Government-backed programs support infrastructure development digital health adoption and awareness campaigns across sleep medicine. Local providers offer cost-effective culturally adapted and mobile-first solutions tailored to regional needs. Demand for scalable and inclusive sleep apnea infrastructure is rising across urban and peri-urban markets. These trends are accelerating regional growth across sleep apnea innovation and deployment.

Key players in the market

Some of the key players in Sleep Apnea Diagnostic and Therapeutic Devices Market include ResMed Inc., Koninklijke Philips N.V., Fisher & Paykel Healthcare Corporation Limited, Drive DeVilbiss Healthcare LLC, Compumedics Limited, BMC Medical Co. Ltd., SomnoMed Limited, Natus Medical Incorporated, Itamar Medical Ltd., Braebon Medical Corporation, Curative Medical Inc., Lowenstein Medical Technology GmbH + Co. KG, Cadwell Industries Inc., Cleveland Medical Devices Inc. and AirAvant Medical Inc.

Key Developments:

In October 2025, ResMed entered a joint venture with Google's Verily, aiming to develop software solutions for diagnosing and managing sleep apnea and related breathing disorders. The U.S.-based venture combined ResMed's clinical expertise with Verily's data analytics capabilities to improve early detection and personalized treatment pathways for millions of undiagnosed patients.

In May 2025, - Philips acquired DiA Imaging Analysis, an AI-powered ultrasound software firm, to strengthen its diagnostic imaging capabilities. While not exclusive to sleep apnea, the acquisition supported Philips' broader strategy to integrate AI into multi-modality diagnostics, including respiratory and sleep-related imaging workflows.

Product Types Covered:

• Diagnostic Devices
• Therapeutic Devices
• Accessories & Consumables

Technologies Covered:

• Diagnostic Technologies
• Therapeutic Technologies

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Platforms
• Direct Sales

Applications Covered:

• Obstructive Sleep Apnea (OSA)
• Central Sleep Apnea (CSA)
• Complex Sleep Apnea Syndrome
• Other Applications

End Users Covered:

• Hospitals
• Sleep Clinics
• Homecare Settings
• Research & Academic Institutions
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Sleep Apnea Diagnostic and Therapeutic Devices Market, By Product Type

• 5.1 Introduction
• 5.2 Diagnostic Devices
• 5.3 Therapeutic Devices
• 5.4 Accessories & Consumables

6 Global Sleep Apnea Diagnostic and Therapeutic Devices Market, By Technology

• 6.1 Introduction
• 6.2 Diagnostic Technologies
  • 6.2.1 Polysomnography (PSG) Systems
  • 6.2.2 Respiratory Polygraphs
  • 6.2.3 Pulse Oximeters
  • 6.2.4 Actigraphy Devices
  • 6.2.5 AI-Enabled Sleep Monitoring
  • 6.2.6 Cloud-Based Data Analytics
• 6.3 Therapeutic Technologies
  • 6.3.1 Positive Airway Pressure (PAP) Devices
  • 6.3.2 Oral Appliances
  • 6.3.3 Adaptive Servo-Ventilation (ASV)
  • 6.3.4 Smart Masks & Accessories
  • 6.3.5 Humidifiers and Comfort Devices
  • 6.3.6 Telemonitoring and Connected Therapy Systems

7 Global Sleep Apnea Diagnostic and Therapeutic Devices Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Online Platforms
• 7.5 Direct Sales

8 Global Sleep Apnea Diagnostic and Therapeutic Devices Market, By Application

• 8.1 Introduction
• 8.2 Obstructive Sleep Apnea (OSA)
• 8.3 Central Sleep Apnea (CSA)
• 8.4 Complex Sleep Apnea Syndrome
• 8.5 Other Applications

9 Global Sleep Apnea Diagnostic and Therapeutic Devices Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Sleep Clinics
• 9.4 Homecare Settings
• 9.5 Research & Academic Institutions
• 9.6 Other End Users

10 Global Sleep Apnea Diagnostic and Therapeutic Devices Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 ResMed Inc.
• 12.2 Koninklijke Philips N.V.
• 12.3 Fisher & Paykel Healthcare Corporation Limited
• 12.4 Drive DeVilbiss Healthcare LLC
• 12.5 Compumedics Limited
• 12.6 BMC Medical Co. Ltd.
• 12.7 SomnoMed Limited
• 12.8 Natus Medical Incorporated
• 12.9 Itamar Medical Ltd.
• 12.10 Braebon Medical Corporation
• 12.11 Curative Medical Inc.
• 12.12 Lowenstein Medical Technology GmbH + Co. KG
• 12.13 Cadwell Industries Inc.
• 12.14 Cleveland Medical Devices Inc.
• 12.15 AirAvant Medical Inc.